Abstract:The aim of the present study was to compare the bioavailability of escitalopram (CAS 128196-01-0) from two escitalopram oxalate (CAS 219861-08-2) tablets (escitalopram 10 mg tablet as test preparation and 10 mg tablet commercially available original tablet of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 19 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a wash-out phase of 14 d. Blood samples for pharmacokinetic profiling were taken up to 156 h post-dose, and escitalopram plasma concentrations were determined with a validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method. Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated. The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively. Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined. Both primary target parameters, AUC(0-infinity) and AUC(0-t) were tested parametrically by analysis of variance (ANOVA) and relative bioavailabilities were 105.1 +/- 10.8% for AUC(0-infinity), 104.9 +/- 11.1% for AUC(0-t). Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC(0-infinity) and AUC(0-t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80%-125%. That means that the test formulation is bioequivalent to the reference formulation for escitalopram.

Pharmacokinetics and Bioequivalence of Citric Acid Tamoxifen Dispersible Tablet in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers

Bioequivalence and Safety of Two Formulations of Tofacitinib Citrate Tablets in Healthy Chinese Volunteers under Fasting and Fed Conditions: Randomized, Open‐Label, 2‐Period, Single‐Dose, Crossover Trials

Studies on bioavailability of naproxen dispersible tablet in volunteers

Pharmacokinetics and Bioequivalence of 2 Kinds of Amoxicillin Dispersible Tablets in Healthy Volunteers

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalence study of fluoxetine capsules in healthy volunteers

Bioequivalence of amlodipine besylate tablets in Chinese healthy volunteers

[Development of Sustained Release Tablet of Tamoxifen Citrate and Its in Vitro Release Profile].

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers

Bioequivalence of Azithromycin Tablets in Healthy Volunteers

Study on the dissolution of tamoxifen citrate tablets of different manufacturers in vitro

Pharmacokinetics and Bioequivalence Studies of Galantamine Hydrobromide Dispersible Tablet in Healthy Male Chinese Volunteers

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Bioequivalence of Acetaminophen Plus Pseudoephedrine Hydrochloride Dispersible Tablets for Children in Healthy Volunteers

Pharmacokinetics and bioequivalence of naproxen sodium sustained release tablets in healthy volunteers

Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Pharmacokinetics of Compound Telmisartan Tablets in Chinese Healthy Volunteers